Status:
COMPLETED
A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia
Lead Sponsor:
Northern Italy Leukemia Group
Conditions:
Acute Myelogenous Leukemia
Eligibility:
All Genders
15-65 years
Phase:
PHASE2
Brief Summary
The study was set up to assess: 1. A two-step, increasing-intensity remission induction phase. A conventional chemotherapy course (ICE, plus G-CSF) was followed, in unresponsive patients, by sequenti...
Detailed Description
Adult AML is a difficult-to-treat illness because of both biological and therapeutic reasons. As to the first point, many patients are aged \>50 years and/or present with significant comorbidity and/...
Eligibility Criteria
Inclusion
- age 15-65 years,untreated AML (de novo, secondary, myelodysplasia-related, granulocytic sarcoma),untreated high-risk myelodysplasia (RAEB, RAEB-T), informed consent
Exclusion
- acute promyelocytic leukemia, comorbidity precluding intensive chemotherapy approaches
Key Trial Info
Start Date :
May 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
581 Patients enrolled
Trial Details
Trial ID
NCT00400673
Start Date
May 1 2000
End Date
October 1 2007
Last Update
April 1 2011
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
USC Ematologia Ospedali Riuniti di Bergamo
Bergamo, BG, Italy, 24128
2
Divisione Ematologia Spedali Civili di Brescia
Brescia, BS, Italy, 25123
3
Divisione di Ematologia e TMO Ospedale San Maurizio
Bolzano, BZ, Italy, 39100
4
Ematologia Azienda Ospedaliera S. Croce e Carle
Cuneo, CN, Italy, 12100